CliffBio
small molecule

QBRELIS

LISINOPRIL

Loss of exclusivityNovember 2035latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameQBRELIS
Active ingredientLISINOPRIL
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2016
Marketing statusRX

Listed patents

PatentExpiresType
9616096November 2035use U-71
10039800November 2035use U-185
10406199November 2035use U-8
12433931November 2035use U-3
10265370November 2035product
9463183November 2035product
11179434November 2035product
9814751November 2035product
10940177November 2035product
11771733November 2035product
12186360November 2035product
12128083November 2035product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QBRELIS patent cliff — loss of exclusivity November 2035 | CliffBio